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Abstract
 .Accessory molecules and cytokines are involved in the immunopathogenesis of multiple sclerosis MS and experimental autoimmune
 .encephalomyelitis EAE in rodent models, and are potential targets for immunotherapy. Evaluation of such experimental therapies
requires appropriate animal models. Therefore, we analysed the expression of selected accessory molecules and cytokines in the brain of
 .marmoset monkeys Callithrix jacchus with acute EAE, a newly described non-human primate model for MS. All animals experienced
active disease clinically and histopathologically with strong resemblance to MS. Perivascular infiltrates of mononuclear cells showed
abundant expression of CD40. CD40 was expressed on macrophages, indicating that T cell priming and macrophage effector functions
 .  .may result from local CD40–CD40L interactions. CD40 ligand CD40L and B7-2 CD86 were also expressed, but to a lower extent,
 .while B7-1 CD80 expression was limited. Both pro-inflammatory and anti-inflammatory cytokines were produced within individual
 .lesions during active disease IFN-a , IFN-g , TNF-a , IL-1a , IL-1b , IL-2, IL-4, IL-10 and IL-12 . This suggests that relative levels rather
than sequential expression of Th1- and Th2-type cytokines determine disease activity. These findings demonstrate the value of EAE in
marmoset monkeys as a model to assess the role of accessory molecules and cytokines in multiple sclerosis, and to evaluate targeted
intervention. q 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
 .Multiple sclerosis MS is a chronic progressive disease
affecting the white matter of the central nervous system
Abbreviations: CD40L–CD40 ligand; CNS, central nervous system;
EAE, experimental autoimmune encephalomyelitis; MAb, monoclonal
antibody; MRI, magnetic resonance imaging; MS, multiple sclerosis
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 .CNS , characterized by neurological dysfunction due to
inflammatory lesions and breakdown of the myelin sheath
which isolates axons. Initially, axons themselves are spared,
but in advanced MS irreversible axonal loss contributes to
neurological symptoms. Mononuclear cell infiltrates are
composed of T cells, monocytesrmacrophages and B cells.
Local interactions between these cell types and brain glia
cells are mediated by accessory molecules and cytokines.
This interplay is thought to trigger effector mechanisms
contributing to inflammation and myelin breakdown re-
.viewed by Lassmann, in press .
Classically, MS has been studied by means of EAE
models in rats and mice Lassmann, 1983; Swanborg,
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.1995 . In these models, animals are immunized with CNS
homogenate or components derived thereof e.g., myelin
.basic protein, proteolipid protein, or peptides mixed in
strong adjuvants, typically Freund’s complete adjuvant.
Subsequently, animals develop clinical signs of disease,
including weight loss and progressively ascending paraly-
sis. Rodent models include monophasic and chronic relaps-
ing patterns of disease, allowing study of both the active
 .relapses, exacerbations and remission phases of the dis-
ease. Extensive experimental evidence indicates that EAE
results from the synergy between myelin-reactive T cells
and antibodies. Inflammation is likely primarily mediated
 .by T cells Swanborg, 1995 , but for demyelination the
involvement of opsonizing antibodies and complement ap-
pears essential Linington and Lassmann, 1987; Linington
.et al., 1992; Genain et al., 1995 . T cell autoreactivity may
be provoked by major and minor myelin constituents like
myelin basic protein, proteolipid protein and myelin oligo-
dendrocyte protein. In addition, non-myelin proteins like
 .S-100b Kojima et al., 1993 , the heat-shock protein
 .alpha-B crystallin Van Noort et al., 1995 , and functional
molecular mimicry between infectious agents and myelin
constituents may be involved Wucherpfennig and Stro-
.minger, 1995 .
In MS and EAE, antigen-specific and non-specific in-
teractions between CNS-infiltrating mononuclear cells and
interactions of these cells with brain glia cells are mediated
by accessory molecules and cytokines. A wide range of
cytokines is involved in the different stages of the disease
Liles and Van Voorhis, 1995; Olsson, 1995; Woodroofe,
.1995 . Several groups have shown that costimulatory
 .  .molecules B7-1 CD80 and B7-2 CD86 play a role in
the disease Cross et al., 1995; Khoury et al., 1995;
Kuchroo et al., 1995; Miller et al., 1995; Perrin et al.,
.1995; Racke et al., 1995; Arima et al., 1996 . We have
recently demonstrated that CD40–CD40L interactions are
crucial in EAE in SJL-mice induced by a peptide of
 .  .proteolipid protein PLP Gerritse et al., 1996 . This139-151
observation was subsequently confirmed in CD40L defi-
 .cient mice Grewal et al., 1996 . In addition, CD40 is
abundantly expressed within the brain of MS patients,
mostly by cells of the monocytic lineage, and therefore we
proposed that CD40–CD40L interactions form a target for
 .therapy in exacerbations of MS Gerritse et al., 1996 .
Similarities in the expression of accessory molecules
and cytokine profiles in the CNS have been found between
rodent EAE models and human MS Olsson, 1995; Swan-
.borg, 1995 . However, important differences also exist,
especially in the pathology of the lesions Lassmann, in
.press , hampering elucidation of MS immunopathogenesis
based on rodent studies. Data from our own laboratories
 .manuscript in preparation and from other groups indicate
that the new EAE model in marmoset monkeys Callithrix
.jacchus closely resembles MS with respect to clinical
presentation, white matter lesion formation in vivo as
 .assessed by magnetic resonance imaging MRI , and CNS
histopathology Genain et al., 1994; McFarland, 1994;
Genain et al., 1995; Massacesi et al., 1995; Genain et al.,
.1996 .
The marmoset EAE model offers several features that
can complement, but not replace, studies in rodents. Com-
 .mon marmosets C. jacchus are small New World mon-
keys. Adult marmosets weigh about 300–400 g, and are
relatively simple and cheap to maintain and handle for
experimental purposes. Marmosets are usually born as
twins with a natural bone marrow chimerism. Hence,
adoptive transfer studies can be done between genetically
distinct siblings. In contrast to the inbred strains used in
rodent models, marmosets are outbred, and as such better
mimick the situation in the human population. Despite
their outbred nature, a high EAE disease incidence of up to
100% can be reached e.g., Massacesi et al., 1995, and this
.study . Because of the close evolutionary relationship be-
tween marmosets and humans, also on the level of im-
munological cross-reactivity, the marmoset EAE model
can be used for efficacy testing of new therapies with
human-specific biological molecules, such as cytokines
and antibody-based constructs. The species-specificity of
many of these molecules makes most rodent models less
valid for evaluation. Marmosets are also excellently suited
for non-invasive imaging of lesion formation within the
CNS by means of MRI, which is an increasingly important
diagnostic method in MS. This allows in vivo studies
followed by detailed immunopathological analysis of
 .MRI-detectable lesions manuscript in preparation . EAE
induced in marmosets by protocols resembling those used
 .for rodents Massacesi et al., 1995 presents itself in a
chronic relapsing-remitting form, which is highly reminis-
cent of human disease. EAE is characterized by mild
neurological signs and perivascular mononuclear cell infil-
trates, large foci of primary demyelination, and reactive
astrogliosis.
In contrast to the available information on clinical
presentation and pathology of EAE, only little is known
about the immunopathogenesis of EAE in non-human pri-
mates in general, and in this new model in particular. We
have therefore analysed the expression of immunologically
relevant molecules, both cytokines and accessory
molecules, which are expressed in the CNS during periods
of active EAE in marmoset monkeys. Strong expression of
CD40 and CD40Lq cells are found in perivascular
mononuclear cell infiltrates throughout the white matter,
suggesting that local CD40–CD40L interactions contribute
to autoimmune effector mechanisms. In addition, pro-in-
flammatory and anti-inflammatory cytokines are simulta-
neously expressed within the same lesion during active
EAE, similar to findings in MS autopsy brain. Our data
provide further insight into the immunopathogenesis of
EAE and MS, and broaden the rational basis for develop-
ment of experimental therapies interfering with the func-
tions of cytokines and accessory molecules, which can be
evaluated in this model.
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2. Materials and methods
2.1. Animals
 .Marmoset monkeys C. jacchus bred at the Biomedical
 .Primate Research Centre BPRC were kept under condi-
tions approved by Dutch laws on animal experimentation.
Experimental protocols were approved by the Institutional
 .Animal Care and User Committee IACUCrDEC after
scientific as well as ethical evaluation. Male animals EB,
EC and EE were 4, 5, and 3 years of age respectively, at
the start of the experiment. Female marmosets ED and EG
were 3 years old. Animal CW, a female animal of 5 years
old suffering from epilepsy, was used as a negative control
with neurological disease other than EAErMS.
2.2. Induction of EAE
EAE was induced essentially as described previously
 .Massacesi et al., 1995 . Per animal, 20 mg of human
 .myelin Van Noort et al., 1994 in PBS was emulsified
with an equal volume of complete Freund’s adjuvant,
containing 3 mgrml of Mycobacterium tuberculosis H37
.RA strain . Intracutaneous injections of 150 ml were di-
vided over four sites on the dorsal axillary and inguinal
regions. On the day of immunization and two days later,
1010 heat-inactivated Bordetella pertussis organisms were
administered i.v. per kg body weight. Animals were sacri-
 .ficed during active disease periods see Fig. 1 by means
of deep sedation with ketamin and intracardiac administra-
tion of pentobarbital. At necropsy one hemisphere was
snap-frozen in liquid nitrogen for immunocytochemistry
and the other hemisphere was fixed in formalin followed
by paraffin embedding for histopathological examination.
2.3. Clinical e˝aluation
Severity of EAE was evaluated daily using a modifica-
tion of the scoring system described by Massacesi et al.
 .1995 . Development of EAE was monitored daily by a
trained observer and the mean score reached in a particular
week was taken as the readout number. It should be noted
that EAE clinical scoring systems in general are not ordi-
nal. However, the grading system for the marmoset is
based on the fact that the disease course usually follows
the sequence listed below, i.e., apathy preceeds lethargy
and so on. Mean scores over a week are used to rule out
incidental peak values which occur for only one day, or
during only a part of a given day.
Clinical score:
0 no disease
0.5 apathy, loss of appetite, altered limb usage without
 .ataxia coordination weakness when walking
1.0 lethargy, anorexiarweight loss, tremors
2.0 ataxia
 .2.5 incomplete paralysis on one side hemiparesis or
 .both sides paraperesis of the body, sensory loss,
brain stem syndrome or blindness
 .3.0 complete paralysis on one hemiplegia or both
 .paraplegia sides of the body
4.0 compete paralysis of all four limbs
2.4. Histopathological e˝aluation
Histopathological evaluation was performed on sections
of paraffin-embedded brain material routinely stained with
hematoxylinreosin, Kluver Barrera myelin stain, and¨
Bielschowsky silver impregnation for visualization of ax-
ons. Parameters evaluated included extent of inflammation,
composition of the infiltrate, extent of demyelination, ac-
tivity of plaques and sites of the brain involved see
.Section 3 for details . Demyelination was scored on multi-
 .ple 10 cross-sections of spinal cord and 6 coronal sec-
tions through the brain. In case of minimal loss of myelin
fibers, the score was qry. When most lesions contain
only perivenular demyelination, the score was q. A score
of qq indicates confluent demyelination: in addition to
perivenular demyelination, plaques have formed in which
demyelination involves several blood vessels.
2.5. Immunocytochemistry
Immunocytochemistry was performed on frozen sec-
tions of marmoset brain to detect expression of cell type
specific markers, accessory molecules and cytokines see
.below for description . The methodology of immunocyto-
chemical procedures used here has been reviewed in detail
previously Claassen and Jeurissen, in press; Hoefakker et
.al., 1995 . In brief, frozen sections of 8 mm were thaw-
mounted on silane coated glass slides and stored overnight
in humidified atmosphere. The next day, sections were
air-dried for 1 h and fixed at room temperature in fresh
 .acetone containing 0.02% vrv H 0 . After air-drying for2 2
10 min, sections were washed with PBS and incubated
with predetermined optimal dilutions of appropriate
 .reagents see below . Specificity of all antibodies had been
evaluated previously on human material by combinations
of ELISA, flow cytometry, and immunocytochemistry. The
latter included inhibition experiments with recombinant
protein. In addition, cross-reactivity with marmoset cy-
tokines was assessed by staining of marmoset spleen sec-
tions.
Fixed sections were incubated with primary reagents
overnight at 48C, in humidified atmosphere. Incubations
with secondary and tertiary reagents were done during 1 h
at room temperature. Between incubation steps, three
washes with PBS were done. Biotinylated antibodies fol-
lowed by avidin–peroxidase or avidin–alkaline phos-
 .phatase Sigma, St. Louis, MO were used for detection of
IL-1a , IL-1b and IL-10. Unconjugated antibodies were
used to detect IL-2, TNF-a , IFN-a and IFN-g . The
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secondary antibody was horse anti-mouse IgG biotin Vec-
.tor Lab., Peterborough, UK , and avidin–peroxidase was
used as the final step. Incubation with AEC 3-amino-9-
.ethylcarbazole substrate for 10 min was used to reveal
 .peroxidase activity bright red translucent precipitate . Af-
ter washing, sections were counterstained with hema-
toxylin, and embedded with glycerol-gelatin. Primary anti-
bodyrreagent omission control stainings were performed
for the different secondaryrtertiary reagents used.
For histochemical revelation of acid phosphatase activ-
ity, fixed sections were incubated for 30 min at 378C with
the appropriate substrate. This consisted of naphtyl AS-
BI-phosphate and pararosanilin in sodium acetaterbarbital
sodium buffer. Double staining for co-expression of CD40
 .on the cell membrane in blue and cytoplasmic acid
 .phosphatase activity in red was performed by staining for
CD40 as above, but staining for acid phosphatase prior to
the final substrate step for alkaline phosphatase activity
 .using naphtol-AS-MX-phosphate and Fast Blue BB base .
2.6. Reagents for detection of accessory molecules and
cytokines
Human-specific reagents used for detection of accessory
cells and cytokines in marmosets are listed below. Cellular
sources of cytokines and their roles in MS and EAE are
reviewed in detail by Olsson, 1995, Liles and Van Voorhis,
.1995 and Brosnan et al., 1995 . References with respect to
functions of accessory molecules in MS and EAE can be
found for instance in Arima et al., 1996; Grewal et al.,
1996 and Racke et al., 1995. Staining for acid phosphatase
by means of the appropriate substrate detects activity of
this enzyme in lysosomes in cells of the monocytic lin-
eage, including monocytesrmacrophages and microglia.
As such, it is a useful marker to detect infiltrating
macrophages within perivascular infiltrates of mononu-
clear cells. Expression of MHC-DR on antigen presenting
 .  .cells APC and involved in presentation of auto -antigens
 .was detected by means of MAb L234 mouse IgG1 kind
.gift of Dr. A. Morgan, Celltech, Slough, U.K. . CD40 as
expressed on APC and involved in costimulation of both T
cells and APC, was detected by means of MAb’s 5D12
 .  . .mouse IgG2b and M2 mouse IgG1 PanGenetics BV .
CD40L as expressed on activated CD4q T cells and
involved in costimulation of both T cells and APC was
 .detected by means of MAb M79 mouse IgG1 kindly
.  .provided by Immunex, Seattle, WA . B7-1 CD80 , ex-
pressed on APC and presumably involved in costimulation
promoting Th1-type responses, was detected by means of
 .MAb 5B5D1 mouse IgG1 a kind gift of Innogenetics
.  .N.V., Gent, Belgium . B7-2 CD86 , expressed on APC
and presumably involved in promoting Th2-type re-
sponses, was detected using MAb 1G10H6 mouse
. .IgG2a a kind gift of Innogenetics N.V., Gent, Belgium .
IFN-a , expressed by B cells, NK cells and macrophages,
and stimulating MHC class I expression was detected by
 .means of MAb MC16 mouse IgG1 a kind gift of Dr. P.
.van der Meide, BPRC . IFN-g , expressed by T cells, NK
cells, macrophages, microglia and astrocytes, and presum-
ably involved in stimulation of inflammation and expres-
sion of MHC class I and II was detected by antibody MD2
 . .mouse IgG1 also a gift from Dr. P. van der Meide .
TNF-a , expressed by T cells macrophages, endothelial
cells, microglia, oligodendrocytes and astrocytes, can stim-
ulate cytokine secretion and may have direct degradating
effects on myelin. TNF-a was detected by means of MAb
 .61E71 mouse IgG1 also a gift from Dr. P. van der
.Meide . IL-1a and IL-1b were detected by MAb VMP18
 .  .mouse IgG1 and VHP20 mouse IgG2a , respectively
 w x .Instituto Ricerche Immunobiologiche IRIS , Siena, Italy .
These cytokines can be produced by macrophages, T and
B cells, NK cells, endothelial cells, microglia and astro-
cytes. They have pro-inflammatory effects and costimulate
activation, maturation and clonal expansion of T and B
cells, increase expression of ICAMs and have chemotactic
activity for macrophages and neutrophils. IL-2 produced
by T cells and astrocytes promotes proliferation and activ-
ity of antigen-specific B and T cells. IL-2 was detected by
 .means of MAb 80-3418-01 mouse IgG1 Genzyme, Naar-
.den, Netherlands . IL-4 produced by Th2 cells,
macrophages and B cells stimulates activation and prolifer-
ation of B cells, secretion of immunoglobulins, prolifera-
tion of T cells, inhibits development of Th1 cells and
stimulates development of Th2 cells, and upregulates MHC
class II expression on macrophages and stimulates phago-
cytic activity. IL-4 was detected by means of MAb 1842-01
 . .mouse IgG1 Genzyme . IL-10 produced by Th2 cells,
macrophages, B cells and astrocytes suppresses
macrophage function and pro-inflammatory cytokine pro-
duction by macrophages, thereby reducing Th1 cytokine
production, it downregulates MHC class II expression, and
increases B cell proliferation. IL-10 was detected by means
 .of MAb MCA B-S10 mouse IgG1 Instruchemie, Hilver-
.sum, Netherlands . IL-12 can be expressed by macrophages
and B cells, promotes growth of T cells and NK cells, and
displays anti-inflammatory activity. Expression of the p35
chain of IL-12 was detected by MAb 1841-D mouse
. .IgG1 Pharmingen, San Diego, CA .
2.7. E˝aluation and quantitation of immunocytochemistry
Two to three independent stainings on two to four
sections were done for each marker, leading to a total of
4–9 brain sections per animal, and antibody immunocyto-
chemical stainings of all individual sections were evalu-
ated by two independent observers, using semi-quantitative
scoring criteria based on previously published systems
 .Massacesi et al., 1995; Windhagen et al., 1995 see leg-
.end of Table 2 . Staining intensity, as described in the
legend of Table 2, refers to the presentation of individual
positively-stained cells. Although staining intensity does
not necessarily reflect physiological importance of the
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 . .Fig. 1. Clinical profile of EAE in marmoset monkeys. The clinical disease score of individual animals over time is indicated in arbitrary units a.u see Section 2 on the left. The weight of monkeys,
expressed as a percentage of the animal’s weight at the start of the experiment is indicated on the right.
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presence of a molecule, it does give information on the
local expression level.
For evaluation and quantitation of stainings, as well as
for photomicrographs, an Olympus Vanox brightfield
photomicroscope was used.
3. Results
3.1. Clinical profile of EAE in marmoset monkeys
All five animals developed disease two to three weeks
 .after immunization 100% incidence , with an individually
 .different course of the disease Fig. 1 . Active inflamma-
tion of the brain was confirmed with MRI manuscript in
.preparation . In addition, all animals eventually progressed
 .to strong clinical disease clinical score 2 or higher .
Moderate to marked weight loss was observed from 10%
.up to 27% in animal EE , which mirrored the severity of
the clinical signs. Animal EB, which was followed for 22
weeks post-induction, had three disease periods of increas-
ing severity. Animals EC and EG followed a similar
pattern, but were followed for a shorter period of time and
had two bouts of active disease. ED developed particularly
rapid and aggressive disease, reaching score 3 within 6
weeks. Animal EE developed limited signs of disease at
first, and then had one severe attack accompanied by major
weight loss, before euthanasia. Animals were sacrificed at
different time points after disease induction, but always
during active disease.
3.2. Histopathology of EAE brain
Since animals were all euthanized during an active
disease period, albeit at different time points after disease
induction, the subsequent analysis of brain tissue by
histopathology and immunocytochemistry was expected to
reflect active engagement of cytokines and accessory
molecules in ongoing local autoimmune responses.
As expected, histopathological evaluation of marmoset
brains affected by active EAE showed multiple foci of
 .inflammation and myelin loss Table 1 . All animals dis-
played inflammatory perivascular infiltrates, but to varying
extents. Different stages of lesion formation were found
within each animal, scattered throughout the brain white
matter. Lesion formation ranged from small perivascular
cuffs of infiltrating mononuclear cells to large confluent
lesions with necrotic centers, the latter mainly located
around the ventricles. Infiltrates consisted of lymphocytes
and monocytesrmacrophages, as has been described for
human MS and rodent EAE models. Granulocytes were
 .only present by exception animal EG . Staining for acid
phosphatase activity, a lysosomal enzyme characteristic for
cells of the monocytic lineage, revealed sometimes mas-
sive numbers of perivascular infiltrating macrophages and
 .activated microglia see also Fig. 2a–d . Varying levels of
myelin loss were found, where EE was notably extreme. In
this animal, in spite of brain inflammation, no myelin loss
or active demyelination were evident despite the fact that
this animal had strong clinical disease and a severe reduc-
tion in body weight. As in human MS, the optic system
was affected in three out of five animals. The sciatic nerve
did not show evidence of inflammation. In two animals a
moderate degree of inflammation was present in the spinal
cord.
3.3. In situ expression of accessory molecules
To assess whether different accessory molecules are
expressed in the brain during EAE, immunocytochemistry
was performed on frozen sections. We focused on CD40–
 .CD40L and B7-1rB7-2 CD80rCD86 in view of the
proposed roles of those molecules in EAE and MS see
Cross et al., 1995; Khoury et al., 1995; Kuchroo et al.,
1995; Miller et al., 1995; Perrin et al., 1995; Racke et al.,
Table 1
Histopathology of EAE brain
Animal Inflam. Infiltrate Macrophages Myelin loss Active Brain Spinal cord Roots N. Ischiadicus
aEB qq Ly, Mo q qq " Opt, Fo qqq y y
EC qq Ly, Mo qqq q q CSO, Opt qq y y
ED q Ly, Mo qq " q CSO, CWM q y y
EE q Ly, Mo qqq y y CSO, Opt meninges q y
EG qqq GrLy, Mo qqq qq, destructive q CSO, Thal qqq q y
 .Abbreviations: CSO, centrum semiovale periventricular white matter ; CWM, cerebellar white matter; Fo, fornix; G, granulocytes; Inflam., inflammation;
Ly, lymphocytes; Men, meninges; Mo, monocytesrmacrophages; Opt, optic system; Thal, thalamus; Inflammation score: 0, no inflammation present; q
 .  .rare, 1–3 perivascular cuffsraverage whole section; qq, moderate numbers 3–10 of perivascular cuffsrsection; qqq, widespread perivascular
cuffing and parenchymal infiltration by inflammatory cells.
Macrophages: number of infiltrates with acid phosphatase activity. Acid phosphatase activity is found in macrophages and activated microglia.
Demyelination: ", single demyelinated fibers; q perivenous demyelination; qq confluent demyelination.
Active: lesional activity as defined by the presence of macrophages containing myelin degradation products.
aActive lesions were only present in the spinal cord, and not in the brain.
Spinal cord: y, no involvement; q, limited involvement; qq, moderate involvement; qqq extensive involvement.
Roots: y, no involvement; q, involvement of roots.
N. ischiadicus: y, no involvement; q, involvement of nerve.
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.1995; Arima et al., 1996 . The results of immunocyto-
chemical stainings are summarized in Table 2, and are
discussed below. Specific stainings were interpreted in
light of the corresponding negative control staining omis-
.sion of the primary antibody . In general, negative control
stainings done by omission of the primary antibody re-
vealed little or no staining. Animal CW, which suffered
from a non-inflammatory neuropathy, i.e., epilepsy, was
used as a non-EAE CNS-disease control. No or only very
limited expression of accessory molecules was found in
this brain tissue.
3.3.1. MHC-DR
Expression of MHC class II, although not an accessory
molecule sensu stricto, was evaluated because of its pivotal
role in antigen presentation to CD4q T cells, proximal to
expression of inducible accessory molecules on T cells and
antigen presenting cells such as CD40L, B7-2 and CTLA4:
.see Roy et al., 1995 and Jaiswal et al., 1996 . EAE-animals
showed mononuclear cells with high levels of expression
of MHC-DR in all infiltrates. Staining was mostly re-
stricted to the perivascular infiltrates. In addition to large
infiltrates, animal EC had many small clusters of positive
cells, and also showed some scattered positive cells in the
parenchyma, possibly representing infiltrating macrophages
or microglia. In the epilepsy control animal CW, a mini-
 .mal number -5 of scattered positive cells was found per
 .section. Fig. 2 i shows an example of MHC-DR expres-
sion in EAE. The pattern of expression found is consistent
with findings in human MS and rodent models, where
class II is mainly found on macrophages, and supports the
view that local interaction between antigen-presenting cells
 .and effector cells macrophages and T cells contributes to
inflammation.
3.3.2. CD40
Four out of five EAE animals had strong expression
 .EC, ED, EE, EG or moderate expression of CD40 on
high numbers of mononuclear cells within multiple infil-
trates. Not all infiltrates contained CD40-positive cells,
possibly pointing at differential expression of this acces-
sory molecule in lesions of different age. CD40 was not
present in sections of animal EB despite active disease and
myelin loss. Animals EE and EG displayed some strongly
positive cells scattered around infiltrates, possibly repre-
senting infiltrating macrophages or local microglia. Intense
CD40 expression was found in large infiltrates as well as
in small cell clusters.
It has been reported that CD40 can be functionally
expressed on endothelium under inflammatory conditions
 .Hollenbaugh et al., 1995; Karmann et al., 1995 . Interest-
ingly, the 5D12 antibody used here to detect CD40 did not
reveal endothelial expression of this molecule. However,
anti-CD40 MAb M2 did stain limited numbers of endothe-
lial cells in animals EC and ED, and more numerous
endothelial cells in EE and EG. Apparently, these two
MAb recognize differentially accessible epitopes on CD40.
This is supported by distinct activities of these MAb in in
 .vitro assays as well Kwekkeboom et al., 1993 . CD40 was
not expressed in control animal CW. Examples of CD40
expression are shown in Fig. 2c,d.
3.3.3. Co-expression of CD40 and acid phosphatase
To assess whether CD40 within perivascular infiltrates
is expressed by cells of the monocytic lineage, similar to
 .MS in humans Gerritse et al., 1996 , double staining for
cell surface CD40 expression and intracytoplasmic acid
phosphatase activity was performed see Fig. 2d for an
.example . In general, in several animals, many double
staining cells were found. CD40 expression by infiltrating
macrophages was not a strict rule as cells single positive
for acid phosphatase could also be found. In addition,
CD40 single positive cells were sometimes found, which
may represent infiltrating B cells. Animal EB did not show
extensive infiltration of the brain by macrophages see also
.Table 1 . Brain sections of animal EC contained abundant
double staining cells, both in small and in larger infiltrates.
In addition, single positive acid phosphatase containing
cells co-localized with CD40 single positive cells. In ani-
mal ED, the majority of acid phosphatase expressing cells
did not express CD40 on the membrane, but a significant
fraction co-expressed CD40 and acid phosphatase. Animal
EE could not be evaluated because of the absence of
infiltrates in the material available for this staining. Animal
EG showed abundant and brightly double stained cells
 .Fig. 2d , and again many cells singly positive for acid
phosphatase were found. A minority of CD40 single posi-
tive cells was also found.
3.3.4. CD40L
CD40L was expressed in brain sections from four out of
five animals with EAE, with the exception of animal EB.
Compared to expression of CD40, CD40L was present at a
much lower level, both with respect to the number of
positive cells, and the staining intensity of individual cells.
Fewer infiltrates contained CD40L-positive cells, the fre-
quency of positive cells per infiltrate and the staining
intensity per cell were considerably lower than of those
expressing CD40. Fig. 2e shows a rare example of more
abundant expression of CD40L within an infiltrate, whereas
Fig. 2f shows the more common pattern of scattered cells
with low expression of CD40L.
3.3.5. CD80rB7-1 and CD86rB7-2
B7-1 expression was limited in terms of number of
animals, number of infiltrates, number of positive cells per
infiltrate, and intensity of staining. An example is shown
in Fig. 2g. Compared to B7-1, B7-2 was expressed in more
 .animals four out of five , and positive infiltrates as well as
 .cells were more frequent Fig. 2h . However, compared to
frequency and level of expression of CD40, B7-2 expres-
sion was quite low.
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 .  .Fig. 2. Expression of accessory molecules and cytokines in marmoset EAE brain. a Acid phosphatase red expressed by infiltrating macrophages and
 .  .  .activated microglia. Low power magnification of a brain section animal EG =40 ; b Detail of a , showing extensive perivascular infiltration by
 . .  .  .  . .  .macrophages red =200 ; c CD40 red expressed on infiltrating mononuclear cells animal EG =100 ; d Doublestaining showing macrophages with
 .  . .cytoplasmic acid phosphatase activity red and membrane CD40 expression blue animal EG . Arrowheads indicate examples of macrophages expressing
 .  .  .  . .  .  .CD40 =650 ; e CD40L red expressed on perivascular mononuclear cells animal EE =200 ; f Scattered CD40L-expressing cells red within an
 . .  .  . . .  .infiltrate animal ED =325 ; g Limited expression of B7-1 arrowheads indicate examples animal EC =325 ; h Expression of B7-2
 . . .  .  . .  .arrowheads animal EE =130 ; i Strong expression of MHC-DR in all infiltrates of all EAE animals animal EE =200 ; j Locally restricted
 .  . .  .  .  .expression of IL-12 within an infiltrate: compare with b both animal EG =325 ; k Expression of IL-1b in a small infiltrate in animal EC =325 ; l
 . .Abundant expression of IL-10 by cells of astrocyte morphology, surrounding a perivascular infiltrate animal EC =200 . Details of staining reagents and
protocols are listed in Section 2.
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 .Fig. 2 continued .
3.4. In situ expression of cytokines
The expression of different pro-inflammatory and anti-
inflammatory cytokines previously found in the CNS of
MS-patients and in rodents with EAE was also investi-
gated in marmosets by means of immunocytochemistry.
Results for the infiltrates are summarized in Table 3 and
are discussed below. The epileptic animal CW was used as
a non-inflammatory neuropathy control. Some staining
associated with the endothelium and inner cell layers
directly surrounding blood vessels was found for some
cytokines. Expression of IFN-a , IL-1a and IFN-g was
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Table 2
Accessory molecules expressed by mononuclear cells infiltrating the
braina
Molecule Animal
EB EC ED EE EG CW
MHC-DR number qq qqq qqq qqq qqq y
intensity qq qq qq qq qq y
CD40 number y qqq qq qqq qqq y
intensity y qq q qq qq y
CD40L number y qqq qq q qq y
intensity y q q q q y
B7-1rCD80 number y qq y q q y
intensity y q y q q y
B7-2rCD86 number y qqq qq qq q y
intensity y q q qrqq q y
a Inflammatory infiltrates were scored with respect to both numbers and
size based on staining for acid phosphatase activity cells of the mono-
.cytic lineage, excluding reactivity in parenchymal microglia as follows.
Numbers: infiltrates; y, no infiltration; q, occasional perivascular cuffs
 .1–3 on average per section; qq, moderate number of perivascular
 .cuffs 4–10 on average per section; qqq, large number of perivascu-
 .lar cuffs )10 per section and infiltration of the parenchyma by acid
phosphatase-positive cells. Size: maximum size score of infiltrates deter-
 .mines final score: q, small infiltrates up to 30 cells ; qq, medium-sized
 .  .infiltrates 30–100 cells ; qqq, large infiltrates more than 100 cells .
Expression of accessory molecules and cytokines was separately evalu-
ated for endothelium and the cell layers directly adjacent to the endothe-
lium, and the infiltrates. Only data for the infiltrates are shown in Table 2.
Numbers of positive cells and staining intensity of individual cells is
shown as follows: Numbers: y, no positive cells; q, occasional perivas-
 .cular cuffs 1–3 containing positive cells on average per section; qq,
 .moderate numbers of perivascular cuffs 4–10 containing positive cells;
 .qqq, large number )10 of perivascular cuffs containing positive
cells. Intensity: q, positive cells with low to moderate staining intensity;
qq, positive cells with high staining intensity.
strong in this location in all EAE animals, whereas TNF-a
expression was more limited. IL-1b was expressed at a
low level in this location in EAE animals EB and EC. IL-2
was expressed at low levels in animals EC, ED, EE, and
EG. IL-12 was found in animals ED and EE. In control
animal CW, strong expression of IFN-g was found here,
as well as a limited expression of IFN-a , TNF-a , and
IL-1a , but no other cytokines.
Expression of cytokines by cells infiltrating the brain
parenchyma or by glia cells was found for IL-10 in all
EAE animals, but only strongly in animal ED. Control
animal CW also showed occasional IL-10 expressing cells
in the parenchyma. Occasional IL-1b expressing cells
were only present in the parenchyma of animal EB. IL-4
was only found in the parenchyma in animal EG, but at
relatively high levels.
3.4.1. IFN-a and IFN-g
IFN-a was expressed on cells within multiple perivas-
cular infiltrates in all animals. Expression was minimal in
animal EB, while EC and ED showed numerous infiltrates
with strongly positive cells. The pattern and extent of
IFN-g expression was very similar to that of IFN-a .
3.4.2. TNF-a
TNF-a expression was more limited than IFN-a and
IFN-g , and staining intensity of individual cells was lower.
Again, animal EB had the lowest expression of the EAE-
affected marmosets, but ED and EE also displayed low
levels.
3.4.3. IL-1a and IL-1b
Extensive expression of IL-1a was found in all EAE
animals, with high staining intensity in all EAE animals
except ED. Often, astrocyte-like cells in the parenchyma
were positive. Compared to IL-1a , expression of IL-1b
was somewhat more limited, with just a few infiltrates per
section containing positive cells in animals ED and EE.
Except in animal EC, staining intensity of individual cells
was low. An example of IL-1b expressing cells is shown
in Fig. 2k. In animal EB, astrocyte-like cells expressing
IL-1b were also found.
3.4.4. IL-2 and IL-4
IL-2 was absent in infiltrates of EAE-affected mar-
mosets EB and ED, while the other EAE animals had low
 .  .EC, ED or moderate EG expression of IL-2. IL-4
expression was more limited than IL-2, being absent in
animal EC and present at low levels in EB, ED and EE. In
this case animal EG formed the exception with some
infiltrates containing cells brightly positive for IL-4. In
addition, this animal displayed individual IL-4 positive
cells with astrocyte-like morphology, surrounding the infil-
trates.
Table 3
Cytokines expressed by mononuclear cells in brain infiltratesa
Cytokine Animal
EB EC ED EE EG CW
IFN-a number q qqq qqq qqq qqq y
intensity q qq qq q q y
IFN-g number qq qqq qqq qqq qqq y
intensity q qq qq qrqq q y
TNF-a number q qqq qq qq qqq y
intensity q q q q qq y
IL-1a number qqq qqq qq qqq qqq y
intensity q qq q qq qq y
IL-1b number q qqq qq q qqq y
intensity q qq q q q y
IL-2 number y qq y qq qqq y
intensity y q y q q y
IL-4 number y y q q qqq y
intensity y y q q qq y
IL-10 number qqq qqq qqq qq qqq q
intensity qq qq qq qq qq q
IL-12 number q q q q qqq y
intensity q q q q qrqq y
aSee legend to Table 2 for quantitation criteria used.
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3.4.5. IL-10
IL-10 was expressed abundantly in most EAE animals
with strong staining of individual cells. The general pattern
was that cells surrounding perivascular infiltrates ex-
pressed high levels of IL-10. These cells had astrocyte-like
morphology. Similar cells expressing IL-10 were found in
the parenchyma surrounding the infiltrate. An example of
this expression pattern is shown in Fig. 2k. Cannella and
Raine have described a similar distribution of IL-10 ex-
pressing cells in human MS material Cannella and Raine,
.1995 . In addition to this pattern, EAE animals often
showed IL-10 expression within small infiltrates. In con-
 .trol animal CW epilepsy control , some cells with astro-
cyte morphology in the brain parenchyma and around
vessels stained positive for IL-10. This staining was clearly
weaker and positive cells were much less frequent than in
EAE animals.
3.4.6. IL-12
IL-12 was only expressed to a considerable extent in
animal EG. An example of IL-12 staining is shown in Fig.
2j. In this case, it is interesting to note that IL-12 produc-
tion was restricted to a ring around the vessel, coinciding
with an area where acid phosphatase activity was absent
 .compare Fig. 2b,j . This suggests that cells other than
macrophages may produce IL-12 locally.
4. Discussion
This report documents the qualitative expression of a
series of immunological key molecules in the CNS of
EAE-affected animals. The main conclusions are that cy-
tokine producing cells and cells expressing costimulatory
molecules are present in perivascular mononuclear cell
infiltrates, which is also the location where demyelination
is found. High expression of CD40 is found and less
pronounced expression of CD40L, B7-1 and B7-2.
4.1. Clinical disease and histopathology
The immunization protocol used induced strong disease
in all five outbred animals of a relapsing-remitting nature
 .in the animals followed for longer periods Fig. 1 . This is
consistent with previous claims that EAE in marmosets in
a clinical sense mirrors human relapsing-remitting MS. In
general, we observed more severe disease than in the study
 .of Massacesi et al. 1995 . This may be due to different
methods used to purify myelin for immunization, the ge-
netic and microbiological status of the animals, or differ-
ences in the adjuvant and B. pertussis preparations. In our
experience in rodent EAE models, seemingly minute modi-
fications in induction protocols can result in markedly
different disease activity. The fact that genetically distinct,
outbred animals were used here may account for individual
variation in kinetics and severity of disease.
As animals in this study were sacrificed during acute
episodes of the disease, we assume that the tissues studied
here only reflected events occurring during periods of
clinically active disease. Histopathological evaluation of
brain tissue revealed that all EAE-animals had inflamma-
tion and infiltration of the brain with lymphocytes and
monocytes. Animal EG showed the most severe and exten-
sive involvement of the brain, including infiltration with
granulocytes, destructive myelin loss, and involvement of
the roots. Animal EE was the only case without myelin
loss or active demyelination, but with involvement of the
roots. In classical MS, the disease process is restricted to
the CNS. However, in Marburg’s type of acute MS, in-
flammation and demyelination in peripheral nerves is com-
 .mon Marburg, 1906 . Importantly, in acute marmoset
EAE, no involvement of the peripheral sciatic nerve was
seen, indicating that the major pathological alterations are
confined to the CNS. Collectively, the histopathological
data are very similar to findings in human MS brain and
thus, support the usefulness of marmosets as a model for
MS also on this level.
4.2. Correlations between clinical disease and im-
munopathology
The general picture emerging from our data is that
clinically severe EAE is accompanied by strong inflamma-
tion of the brain, and myelin loss. MHC-DR and CD40 are
strongly expressed, whereas expression of CD40L, B7-1
and B7-2 are much more limited. The level of cytokine
expression roughly correlated with the number of infiltrat-
ing macrophages, with EC, EE, and EG having the highest
local presence of cytokines. Pro-inflammatory and anti-in-
flammatory cytokines were co-expressed during marmoset
EAE. This too, is in agreement with the expression pattern
of cytokines observed in MS lesions Woodroofe and
Cuzner, 1993; Cannella and Raine, 1995; McFarland,
.1995 . Animal EB is clearly an exception to the rule, as
this animal showed outspoken clinical disease score around
.2.5 , considerable expression of MHC-DR, but none of the
other accessory molecules. In addition, EB had minimal
presence of the different cytokines evaluated. This differ-
ence could be due to the fact that in this animal, the bulk
of the active lesions was found in the spinal cord. In the
brain tissue that was used for evaluation of accessory
molecules and cytokines, the limited number of lesions
would preclude detection of these molecules.
4.3. Accessory molecules: CD40–CD40L
We analyzed the role of accessory molecules in mar-
moset EAE in view of reports by us and others of their
involvement in MS and EAE. CD40–CD40L interactions
between CD40L on activated CD4q T cells and CD40 on
B cells, dendritic cells and follicular dendritic cells are
crucial for the initiation of antibody responses against
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pathogens, isotype switching and memory formation re-
viewed by Laman et al., 1996; Van Kooten and Banchereau,
.1996 . CD40 can also be functionally expressed on
 .macrophages Alderson et al., 1993 , and mediates T
cell-macrophage interactions Wiley and Harmsen, 1995;
Campbell et al., 1996; Kamanaka et al., 1996; Soong et al.,
.1996; Stout et al., 1996 . CD40 is expressed during chronic
inflammation in atherosclerotic plaques Laman et al.,
.1997 . CD40L also has a role in thymic selection of T cells
 .Foy et al., 1995 , and CD40–CD40L interactions are
involved in experimental autoimmune disease such as col-
 .lagen-induced arthritis Durie et al., 1993 and lupus
 .nephritis Mohan et al., 1995 . Interestingly, recent studies
 .in systemic lupus erythematosus SLE patients have shown
that increased CD40L expression is involved in this clini-
cal autoimmune condition Desai-Mehta et al., 1996; Koshy
.et al., 1996 .
By in vivo blocking experiments, we previously showed
that CD40–CD40L interactions are crucial to development
of EAE in SJL-mice. In addition, it was found that CD40
is abundantly expressed by infiltrating macrophages in
autopsy brain material of MS-patients, while CD40L-ex-
 .pression is more limited Gerritse et al., 1996 . The current
study demonstrates that analogous to MS, in marmoset
EAE the brain is infiltrated by macrophages expressing
 .high levels of CD40 Fig. 2c,d . A minority of CD40-posi-
tive cells lacking acid phosphatase activity was found as
well, which may represent B cells analogous to human MS
brain. Although to a much lower extent than CD40, CD40L
 .was also expressed locally Fig. 2e,f . The low level of
CD40L expression may partly result from the different
downregulatory mechanisms described for this molecule
 .Yellin et al., 1994; Van Kooten and Banchereau, 1996 .
In what ways may local interactions between CD40L on
activated T cells and CD40 on macrophages contribute to
disease? First, signals through CD40 are involved in T cell
priming Van Essen et al., 1995; Grewal et al., 1995;
.Grewal and Flavell, 1996; Grewal et al., 1996 . In agree-
ment with this, it was shown recently that production of
 .both Th1 cytokines IL-2, IFN-g and Th2 cytokines
 .IL-4, IL-5 and IL-10 by human T cells is strongly
 .enhanced by CD40L ligation Peng et al., 1996 . Impor-
tantly, in progressive MS, activated CD4q T cells stimu-
 .late increased IL-12 production Balashov et al., 1997 .
Second, activated T cells expressing CD40L can induce
relevant macrophage effector functions. A multitude of
studies, including in vivo depletion experiments, has shown
that macrophages are crucial for development of EAE
 .Huitinga et al., 1995 . Macrophages with different activa-
tion markers characterize demyelinating lesions of distinct
 .stages in human MS-brain Bruck et al., 1995 .¨
Macrophages can contribute directly to myelin damage by
a wide range of effector functions, such as production of
cytokines, proteolytic enzymes, nitric oxide, reactive oxy-
gen species, and lipid peroxidation. Macrophages can also
indirectly affect the inflammatory process and demyelina-
 .tion by expression of MHC class II, auto -antigen pre-
sentation, and secretion of compounds affecting other cell
types.
Several studies have demonstrated that ligation of CD40
activates macrophage functions that potentially contribute
to EAE and MS. CD40 ligation leads to adherence of
macrophages to CD40L-expressing cells Alderson et al.,
.1993 , homotypic aggregation and increased survival of
 .cells in culture Kiener et al., 1995 . CD40L induced
 .increased expression of CD54 ICAM-1 , MHC class II,
 .CD86 B7-2 and CD40, improving the antigen presenta-
 .tion function of macrophages Kiener et al., 1995 . Func-
tionally, CD40L supplied a costimulus for production of
the pro-inflammatory cytokines TNF-a , IL-1b , IL-6, IL-8
and IL-12 Alderson et al., 1993; Wagner et al., 1994;
.Kiener et al., 1995; Shu et al., 1995; Kennedy et al., 1996 .
 .Stuber et al. 1996 have shown that anti-CD40L MAb
 .MR1 inhibits IL-12 production in mice, which may
prevent priming of Th1-cells. This mechanism may be
responsible for the prevention of EAE induction in mice
by anti-CD40L MAb reported previously Gerritse et al.,
.1996 . We found very limited IL-12 expression in EAE-af-
 .fected marmosets only animal EG , but this concerned
 .IL-12p35. Kato et al. 1996 have shown that in the mouse,
production of IL-12p40 but not p35 is regulated through
CD40L.
With respect to non-cytokine effector mechanisms of
macrophages, it has been shown that CD40L can enhance
production of cytotoxic NO production by murine
 .macrophages Tian et al., 1995 . The inducible form of
 .NO-synthase iNOS is activated in macrophages in MS
 .brain Bagasra et al., 1995 . CD40L, IL-12 and NO pro-
duction are also linked in cell-mediated immunity against
 .Pneumocystis carinii Wiley and Harmsen, 1995 and
Leishmania species Campbell et al., 1996; Kamanaka et
.al., 1996; Soong et al., 1996 .
4.4. Accessory molecules: B7-1rB7-2
Several studies have investigated whether B7-1 and
B7-2 costimulation is involved in EAErMS in the light of
preferential Th1 vs. Th2 activation Cross et al., 1995;
Khoury et al., 1995; Kuchroo et al., 1995; Miller et al.,
.1995; Perrin et al., 1995; Racke et al., 1995 . These studies
are conflicting to some extent, probably partly due to the
different experimental approaches used. Collectively, these
studies do seem to support the hypothesis that B7-1 and
B7-2 differentially signal development of Th1 and Th2
cells, respectively. B7-1 would therefore have a key role in
initiation and perpetuation of Th1-mediated autoimmune
 .diseases, such as MSrEAE. Windhagen et al. 1995 have
evaluated expression of B7-1 and B7-2 in relation to IL-12
production in human MS brain. These authors found in-
creased expression of B7-1 and IL-12p40 in acute MS-
plaques, particularly from early disease cases. B7-2 was
expressed on macrophages both in inflammatory infarcts
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and MS lesions. In our marmoset EAE material, B7-1
expression was particularly low, and B7-2 somewhat higher
but still very limited as compared to CD40. In this respect,
our findings do not seem to support an inductive role of
B7-1. Whether these different levels of expression translate
into functional differences is of course unknown at this
point.
4.5. Cytokine expression in marmoset EAE
Current views on the role of cytokines in MSrEAE
hold that the cytokines IL-1, IL-2, TNF-a , TNF-b and
IFN-g contribute to inflammation and disease, whereas the
cytokines IL-4, IL-10, IFN-b and TGF-b have anti-in-
flammatory properties. This correlates with Th1-Th2 pre-
ponderance. Sequential expression of these cytokines has
been found during induction, overt disease and recovery
 .Brosnan et al., 1995; Olsson, 1995 . However, in an
extensive and detailed analysis of cytokine and adhesion
molecule expression in MS lesions of different activation
 .stages, Cannella and Raine 1995 did not identify any
expression pattern specific for MS. Notably, simultaneous
expression of pro-inflammatory and anti-inflammatory cy-
tokines was found within individual lesions, arguing against
simple straightforward relationships between expression
and disease activity. Most likely, lesions of different age
and activity with differential cytokine patterns can co-exist
see Brosnan et al., 1995 and McFarland, 1995, for more
.extensive discussion of these issues . It is of note that
some anti-inflammatory cytokines such as IL-4 are essen-
tial for antibody production, and that autoantibodies syner-
gize with pro-inflammatory T cells in lesion formation
Linington and Lassmann, 1987; Linington et al., 1992;
.Genain et al., 1995 .
The data of the current study are consistent with the
above in the sense that pro-inflammatory and anti-in-
flammatory cytokines were co-expressed in marmoset EAE
brain during active disease. We did not evaluate kinetics of
expression during course of the disease, as has been done
in rodents, since we studied animals in active disease
periods only. However, material did include brains from
the first, second, and third attack of the disease. The
experiments therefore, support the view that the balance of
relative expression of disease-inducing cytokines and
downmodulatory ones determines the level of clinical signs,
more than sequential expression. Further improvement in
the discrimination of early vs. late and active vs. inactive
lesions will shed more light on the role of cytokines. We
are investigating these issues using MRI-directed im-
munopathological approaches, using gadolinium enhance-
ment of blood brain barrier damage as a marker for early
development of lesions. The importance of detailed analy-
sis of cytokine profiles in situ is underscored by recent
 .data of Genain et al. 1996 that immune deviation therapy
aiming to induce T cell tolerance induction can lead to
 .unexpected fatal disease see also McFarland, 1996 .
4.6. Conclusion
This communication shows that EAE in marmosets
allows evaluation of experimental therapies for MS target-
ing accessory molecules or cytokines. Safety and efficacy
of novel therapeutic molecules which are suitable for use
in humans, such as humanized monoclonal antibodies,
recombinant cytokines and accessory molecules, or small-
molecule inhibitors, can be tested preclinically in this
model. Collectively, our previous data Gerritse et al.,
.1996 and the present findings argue that CD40–CD40L
interactions are operational in peptide-induced EAE in
mice, whole myelin-induced EAE in marmosets, and natu-
rally occurring MS in humans. We propose that local
CD40–CD40L interactions in the CNS form a target for
therapy of MS at different levels. CD40–CD40L interac-
tions can lead to local priming of T cells and cytokine
production. In addition, effector functions of macrophages
relevant to EAErMS may be triggered through CD40.
Finally, local T–B cell interactions may result in produc-
tion of auto-antibodies. The challenge is to pinpoint which
T cell and macrophage functions are indeed triggered by
CD40–CD40L interactions in vivo, and whether and to
what extent such interactions are antigen dependent. Based
on such knowledge, CD40–CD40L targeted therapy of
exacerbations may result in clinical benefit for multiple
sclerosis patients.
Acknowledgements
The expert technical assistance of Bas Groen Depart-
ment of Pharmacology, TNO Prins Maurits Laboratorium,
.Rijswijk, Netherlands in motoric and behavioural assays
of marmosets is gratefully acknowledged. We thank Drs.
Kees Lucas and Hans van Noort for critical reading of the
manuscript. This work was supported by grants number
94-171 MS and 95-221 MS of the Netherlands Foundation
for the support of MS Research Stichting Vrienden MS
.Research and by grant number CT94-0071 of the Euro-
pean Union Human Capital and Mobility Program.
References
Alderson, M.R., Armitage, R.J., Tough, T.W., Strockbine, L., Fanslow,
W.C., Spriggs, M.K., 1993. CD40 expression by human monocytes:
regulation by cytokines and activation of monocytes by the ligand for
CD40. J. Exp. Med. 178, 669–674.
Arima, T., Rehman, A., Hickey, W.F., Flye, M.W., 1996. Inhibition by
CTLA-4Ig of experimental allergic encephalomyelitis. J. Immunol.
156, 4916–4924.
Bagasra, O., Michaels, F.H., Zheng, Y.M., Bobroski, L.E., Spitsin, S.V.,
Fu, Z.F., Tawadros, R., Koprowski, H., 1995. Activation of the
inducible form of nitric oxide synthase in the brains of patients with
multiple sclerosis. Proc. Natl. Acad. Sci. U.S.A. 92, 12041–12045.
Balashov, K.E., Smith, D.R., Khoury, S.J., Hafler, D.A., Weiner, H.L.,
1997. Increased interleukin 12 production in progressive multiple
( )J.D. Laman et al.rJournal of Neuroimmunology 86 1998 30–4544
sclerosis: induction by activated CD4q T cells via CD40 ligand.
Proc. Natl. Acad. Sci. U.S.A. 94, 599–603.
Brosnan, C.F., Cannella, B., Battistini, L., Raine, C.S., 1995. Cytokine
localization in multiple sclerosis lesions. Correlation with adhesion
molecule expression and reactive nitrogen species. Neurol. 45, 16–21,
Suppl. 6.
Bruck, W., Porada, P., Poser, S., Rieckmann, P., Hanefeld, F., Kret-¨
zschmar, H.A., Lassmann, H., 1995. Monocytermacrophage differen-
tiation in early multiple sclerosis lesions. Ann. Neurol. 38, 788–796.
Campbell, K., Ovendale, P.J., Kennedy, M.K., Fanslow, W.C., Reed,
S.G., Maliszewski, C.R., 1996. CD40 ligand is required for protective
cell-mediated immunity to Leishmania major. Immunity 4, 283–289.
Cannella, B., Raine, C.S., 1995. The adhesion molecule and cytokine
profile of multiple sclerosis lesions. Ann. Neurol. 37, 425–435.
 .Claassen, E., Jeurissen, S.H.M. in press . A step by step guide to in situ
immune response analysis of lymphoid tissues by immunohistochemi-
cal methods. In: Weir, D.M., Blackwell, C., Herzenberg, L., Herzen-
 .berg, L. Eds. , Handbook of Experimental Immunology, 5th edn.,
Blackwell Scientific Publications.
Cross, A.H., Girard, T.J., Giacoletto, K.S., Evans, R.J., Keeling, R.M.,
Lin, R.F., Trotter, J.L., Karr, R.W., 1995. Long-term inhibition of
murine experimental autoimmune encephalomyelitis using CTLA-4-Fc
supports a key role for CD28 costimulation. J. Clin. Invest. 95,
2783–2789.
Desai-Mehta, A., Lu, L., Ramsey-Goldman, R., Datta, S.K., 1996. Hyper-
expression of CD40 ligand by B and T cells in human lupus and its
role in pathogenic autoantibody production. J. Clin. Invest. 97, 2063–
2073.
Durie, F.H., Fava, R.A., Foy, T.M., Aruffo, A., Ledbetter, J.A., Noelle,
R.J., 1993. Prevention of collagen-induced arthritis with an antibody
to gp39, the ligand for CD40. Sci. 261, 1328–1330.
Foy, T.M., Page, D.M., Waldschmidt, T.J., Schoneveld, A., Laman, J.D.,
Masters, S.R., Tygrett, L., Ledbetter, J.A., Aruffo, A., Claassen, E.,
Xu, J.C., Flavell, R.A., Ohen, S., Hedrick, S.M., Noelle, R.J., 1995.
An essential role for gp39, the ligand for CD40, in thymic selection.
J. Exp. Med. 182, 1377–1388.
Genain, C.P., Lee-Parritz, D., Nguyen, M.-H., Massacesi, L., Joshi, N.,
Ferrante, R., Hoffman, K., Moseley, M., Letvin, N.L., Hauser, S.L.,
1994. In healthy primates, circulating autoreactive T cells mediate
autoimmune disease. J. Clin. Invest. 94, 1339–1345.
Genain, C.P., Nguyen, M.-H., Letvin, N.L., Pearl, R., Davis, R.L.,
Adelman, M., Lees, M.B., Linington, C., Hauser, S.L., 1995. Anti-
body facilitation of multiple sclerosis-like lesions in a non-human
primate. J. Clin. Invest. 96, 2966–2974.
Genain, C.P., Abel, K., Belmar, N., Villinger, F., Rosenberg, D.P.,
Linington, C., Raine, C.S., Hauser, S.L., 1996. Late complications of
immune deviation therapy in a nonhuman primate. Sci. 247, 2054–
2057.
Gerritse, K., Laman, J.D., Noelle, R.J., Aruffo, A., Ledbetter, J.A.,
Boersma, W.J.A., Claassen, E., 1996. CD40–CD40 ligand interac-
tions in experimental allergic encephalomyelitis and multiple sclero-
sis. Proc. Natl. Acad. Sci. U.S.A. 93, 2499–2504.
Grewal, I.S., Xu, J., Flavell, R.A., 1995. Impairment of antigen-specific T
cell priming in mice lacking CD40 ligand. Nature 378, 617–620.
Grewal, I.S., Foellmer, H.G., Grewal, K.D., Xu, J., Hardardottir, F.,
Baron, J.L., Janeway, C.A., Flavell, R.A., 1996. Requirement for
CD40 ligand in costimulation induction, T cell activation, and experi-
mental allergic encephalomyelitis. Sci. 273, 1864–1867.
Grewal, I.S., Flavell, R.A., 1996. A central role of CD40 ligand in the
regulation of CD4q T cell responses. Immunol. Today 17, 410–414.
Hoefakker, S., Boersma, W.J.A., Claassen, E., 1995. Detection of human
cytokines in situ using antibody and probe based methods. J. Im-
munol. Meth. 185, 149–175.
Hollenbaugh, D., Mischel-Petty, N., Edwards, C.P., Simon, J.C., Denfeld,
R.W., Kiener, P.A., Aruffo, A., 1995. Expression of functional CD40
by vascular endothelial cells. J. Exp. Med. 182, 33–40.
Huitinga, I., Ruuls, S.R., Jung, S., Van Rooijen, N., Hartung, H.-P.,
Dijkstra, C.D., 1995. Macrophages in T cell line mediated, demyelina-
tion and chronic relapsing experimental autoimmune encephalomyeli-
tis in Lewis rats. Clin. Exp. Immunol. 100, 344–351.
Jaiswal, A.I., Dubey, C., Swain, S.L., Croft, M., 1996. Regulation of
CD40 ligand expression on naive CD4 T cells: a role for TCR but not
co-stimulatory signals. Int. Immunol. 8, 275–285.
Kamanaka, M., Yu, P., Yasui, T., Yoshida, K., Kawabe, T., Horii, T.,
Kishimoto, T., Kikutani, H., 1996. Protective role of CD40 in Leish-
mania major infection at two distinct phases of cell-mediated immu-
nity. Immunity 4, 275–281.
Karmann, K., Hughes, C.C., Schechner, J., Fanslow, W.C., Pober, J.S.,
1995. CD40 on human endothelial cells: inducibility by cytokines and
functional regulation of adhesion molecule expression. Proc. Natl.
Acad. Sci. U.S.A. 92, 4342–4346.
Kato, T., Hakamada, R., Yamane, H., Nariuchi, H., 1996. Induction of
IL-12 p40 messenger RNA expression and IL-12 production of
macrophages via CD40–CD40 ligand interaction. J. Immunol. 156,
3932–3938.
Kennedy, M.K., Picha, K.S., Fanslow, W.C., Grabstein, K.H., Alderson,
M.R., Clifford, K.N., Chin, W.A., Mohler, K.M., 1996. CD40rCD40
ligand interactions are required for T cell-dependent production of
interleukin-12 by mouse macrophages. Eur. J. Immunol. 26, 370–378.
Khoury, S.J., Akalin, E., Chandraker, A., Turka, L.A., Linsley, P.S.,
Sayegh, M.H., Hancock, W.W., 1995. CD28-B7 costimulatory block-
ade by CTLA4Ig prevents actively induced experimental autoimmune
encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the
central nervous system. J. Immunol. 155, 4521–4524.
Kiener, P.A., Moran-Davis, P., Rankin, B.M., Wahl, A.F., Aruffo, A.,
Hollenbaugh, D., 1995. Stimulation of CD40 with purified soluble
gp39 induces pro-inflammatory responses in human monocytes. J.
Immunol. 155, 4917–4925.
Kojima, K., Berger, Th., Lassmann, H., Hinze-Selch, D., Zhan, Y., Lu,
H., Lassmann, H., Wekerle, H., 1993. Experimental autoimmune
panencephalitis and uveoretinitis transferred to the Lewis rat by
T-lymphocytes specific for the S-100b molecule, a calcium-binding
protein of astroglia. J. Exp. Med. 180, 817–829.
Koshy, M., Berger, D., Crow, M.K., 1996. Increased expression of CD40
ligand on systemic lupus erythematosus lymphocytes. J. Clin. Invest.
98, 826–837.
Kuchroo, V.K., Prabhu Das, M., Brown, J.A., Ranger, A.M., Zamvil,
S.S., Sobel, R.A., Weiner, H.L., Nabavi, N., Glimcher, L.H., 1995.
B7-1 and B7-2 costimulatory molecules activate differentially the
Th1rTh2 developmental pathways: application to autoimmune dis-
ease therapy. Cell 80, 707–718.
Kwekkeboom, J., De Boer, M., Mevissen, M.L.C.M., Tager, J.M., De
Groot, C., 1993. Signalling via CD40 plays an essential role in the
activation of human B cells by murine EL4B5 cells. Immunol. 79,
439–445.
Laman, J.D., Claassen, E., Noelle, R.J., 1996. Functions of CD40 and its
ligand, gp39. Crit. Rev. Immunol. 16, 59–108.
Laman, J.D., De Smet, B.J.L.G., Schoneveld, A., van Meurs, M., 1997.
CD4–CD4L interactions in atherosclerosis. Immunol. Today 18, 272–
277.
 .Lassmann, H. in press Multiple sclerosis pathology. In: McAlpine’s
Multiple Sclerosis, 3rd edn.
Lassmann, H., 1983. Comparative neuropathology of chronic experimen-
tal allergic encephalomyelitis and multiple sclerosis. Neurology se-
ries, Vol. 25. Springer, Berlin.
Linington, C., Lassmann, H., 1987. Antibody responses in chronic relaps-
ing experimental allergic encephalomyelitis: correlation of serum
demyelinating activity with the antibody titre to the myelinroligo-
 .dendrocyte glycoprotein MOG . J. Neuroimmunol. 17, 61–69.
Linington, C., Engelhardt, B., Kapocs, G., Lassmann, H., 1992. Induction
of persistently demyelinated lesions in the rat following the repeated
adoptive transfer of encephalitogenic T cells and demyelinating anti-
body. J. Neuroimmunol. 40, 219–224.
Liles, W.C., Van Voorhis, W.C., 1995. Nomenclature and biologic
( )J.D. Laman et al.rJournal of Neuroimmunology 86 1998 30–45 45
significance of cytokines involved in inflammation and the host
immune response. J. Inf. Dis. 172, 1573–1580.
Marburg, O., 1906. Die sogenannte "akute Multiple Sklerose". Jahrb.
Psychiatrie 27, 211–312.
Massacesi, L., Genain, C.P., Lee-Parritz, D., Letvin, N.L., Canfield, D.,
Hauser, S.L., 1995. Active and passively induced experimental au-
toimmune encephalomyelitis in common marmosets: a new model for
multiple sclerosis. Ann. Neurol. 37, 519–530.
McFarland, H.F., 1994. Significance of autoreactive T cells in diseases
such as multiple sclerosis using an innovative primate model. J. Clin.
Invest. 94, 921–922.
McFarland, H.F., 1995. The multiple sclerosis lesion. Ann. Neurol. 37,
419–421.
McFarland, H.F., 1996. Complexities in the treatment of autoimmune
disease. Sci. 247, 2037–2038.
Miller, S.D., Vanderlugt, C.L., Lenschow, D.J., Pope, J.G., Karandikar,
N.J., Dal Canto, M.D., Bluestone, J.A., 1995. Blockade of CD28rB7-
1 interaction prevents epitope spreading and clinical relapses of
murine EAE. Immunity, 739–745.
Mohan, C., Shi, Y., Laman, J.D., Datta, S.K., 1995. Interaction between
CD40 and its ligand gp39 in the development of murine lupus
nephritis. J. Immunol. 154, 1470–1480.
Olsson, T., 1995. Critical influences of the cytokine orchestration on the
outcome of myelin antigen-specific T-cell autoimmunity in experi-
mental autoimmune encephalomyelitis and multiple sclerosis. Im-
munol. Rev. 144, 245–268.
Peng, X., Kasran, A., Warmerdam, P.A.M., De Boer, M., Ceuppens, J.L.,
1996. Accessory signaling by CD40 for T cell activation: induction of
Th1 and Th2 cytokines and synergy with interleukin-12 for inter-
feron-g production. Eur. J. Immmunol. 26, 1621–1627.
Perrin, P.J., Scott, D., Quigley, L., Albert, P.S., Feder, O., Gray, G.S.,
Abe, R., June, C.H., Racke, M.K., 1995. Role of B7:CD28rCTLA-4
in the induction of chronic relapsing experimental allergic en-
cephalomyelitis. J. Immunol. 154, 1481–1490.
Racke, M.K., Scott, D.E., Quigley, L., Gray, G.S., Abe, R., June, C.H.,
 .  .Perrin, P.J., 1995. Distinct roles for B7-1 CD80 and B7-2 CD86 in
the initiation of experimental allergic encephalomyelitis. J. Clin.
Invest. 96, 2195–2203.
Roy, M., Aruffo, A., Ledbetter, J.A., Linsley, P., Kehry, M., Noelle, R.J.,
1995. Studies on the interdependence of gp39 and B7 expression and
function during antigen-specific immune responses. Eur. J. Immunol.
25, 596–603.
Shu, U., Kiniwa, M., Wu, C.Y., Maliszewski, C., Vezzio, N., Hakimi, J.,
Gately, M., Delespesse, G., 1995. Activated T cells induce inter-
leukin-12 production by monocytes via CD40–CD40 ligand interac-
tion. Eur. J. Immunol. 25, 1125–1128.
Soong, L., Xu, J.-C., Grewal, I.S., Kima, P., Sun, J., Longley, B.J.,
Ruddle, N.H., McMahon-Pratt, D., Flavell, R.A., 1996. Disruption of
CD40–CD40 ligand interactions results in an enhanced susceptibility
to Leishmania amazonensis infection. Immunity 4, 263–273.
Stout, R.D., Suttles, J., Xu, J., Grewal, I.S., Flavell, R.A., 1996. Impaired
T cell macrophage activation in CD40 ligand-deficient mice. J. Im-
munol. 156, 8–11.
Stuber, E., Strober, W., Neurath, M., 1996. Blocking the CD40L–CD40
interaction in vivo specifically prevents the priming of T helper 1
cells through the inhibition of interleukin 12 secretion. J. Exp. Med.
183, 693–698.
Swanborg, R.H., 1995. Animal models of human disease: Experimental
autoimmune encephalomyelitis in rodents as a model for human
demyelinating disease. Clin. Immunol. Immunopathol. 77, 4–13.
Tian, L., Noelle, R.J., Lawrence, D.A., 1995. Activated T cells enhance
nitric oxide production by murine splenic macrophages through gp39
and LFA-1. Eur. J. Immunol. 25, 306–309.
Van Essen, D., Kikutani, H., Gray, D., 1995. CD40 ligand-transduced
co-stimulation of T cells in the development of helper function.
Nature 378, 620–623.
Van Kooten, C., Banchereau, J., 1996. CD40–CD40 ligand, a multifunc-
tional receptor-ligand pair. Adv. Immunol. 61, 1–77.
Van Noort, J.M., El Ouagmiri, M., Boon, J., Van Sechel, A.C., 1994.
Fractionation of central nervous system myelin proteins by reversed
phase high-performance liquid chromatography. J. Chromatogr. 653,
155–161.
Van Noort, J.M., Van Sechel, A.C., Bajramovic, J.A., El Ouagmiri, M.,
Polman, C.H., Lassmann, H., Ravid, R., 1995. The small heat-shock
protein alphaB-crystallin as candidate autoantigen in multiple sclero-
sis. Nature 375, 798–801.
Wagner, D.H., Stout, R.D., Suttles, J., 1994. Role of the CD40–CD40
ligand interaction in CD4q T cell contact-dependent activation of
monocyte interleukin-1 synthesis. Eur. J. Immunol. 24, 3148–3154.
Wiley, J.A., Harmsen, A.G., 1995. CD40 ligand is required for resolution
of Pneumocystis carinii pneumonia in mice. J. Immunol. 155, 3525–
3529.
Windhagen, A., Newcombe, J., Dangond, F., Strand, C., Woodroofe,
M.N., Cuzner, M.L., Hafler, D.A., 1995. Expression of costimulatory
 .  .molecules B7-1 CD80 , B7-1 CD86 and interleukin 12 cytokine in
multiple sclerosis lesions. J. Exp. Med. 182, 1985–1996.
Woodroofe, M.N., 1995. Cytokine production in the central nervous
system. Neurol. 45, 6–10, Suppl. 6.
Woodroofe, M.N., Cuzner, M.L., 1993. Cytokine mRNA expression in
inflammatory multiple sclerosis lesions: detection by nonradioactive
in situ hybridization. Cytokine 5, 583–588.
Wucherpfennig, K.W., Strominger, J.L., 1995. Molecular mimicry in T
cell-mediated autoimmunity: viral peptides activate human T cell
clones specific for myelin basic protein. Cell 80, 695–705.
Yellin, M.J., Sippel, K., Inghirami, G., Covey, L.R., Lee, J.J., Sinning, J.,
Clark, E.A., Chess, L., Lederman, S., 1994. CD40 molecules induce
down-modulation and endocytosis of T cell surface T cell–B cell
activating moleculerCD40-L Potential role in regulating helper effec-
tor function. J. Immunol. 152, 598–608.
